VC firm blog
Everything we hold that Uniseed published.
Every article we hold from Uniseed.
Australian biotech Currus Biologics has won US regulatory clearance to begin human testing of its lead cancer therapy, CUR-001, combining an antibody platform with CAR T cells for solid tumours.
Melbourne biotech Kinoxis completed a $6.75 million round with new backer MainSequence and won a $2.5 million government-funded CUREator+ grant for dementia and pain drug development; MainSequence's Elaine Stead joins the board.
Also Startup Daily·Startup Daily·Dealroom·This Week in Australian Startups·Dynamic Business
Melbourne biotech ENA Respiratory has begun dosing participants in the second part of its Phase IIa trial of INNA-051; its investor lineup, past government funding awards and BLUE KNIGHT alumni status are recapped.
Melbourne respiratory drug developer ENA Respiratory wins A$2.98 million from incubator Biointelect Venturer's first funding round to support an asthma study of its INNA-051 nasal antiviral.
Under Brandon Capital portfolio ·leads this story in the feed
The US medicines regulator has granted Fast Track designation to Aravax's peanut-allergy immunotherapy PVX108, easing its development path; the Melbourne-based biotech expects Phase 2 data later in 2026.
Uniseed announces portfolio company BioScout's A$6.75 million round co-led by Demea Sustainable Investment and Astanor to scale its crop disease sensor network internationally.
xCystence Bio secured pre-seed funding from Uniseed, Monash Ventures, Breakthrough Victoria, and BioCurate to develop targeted protein degraders for treating genetic kidney disease.
Uniseed-backed Australian medtech Q-Sera's blood-clotting tube technology has debuted in Japan via Terumo's VenoJect II launch; the post also credits MRCF and UniQuest Extension Fund as backers.
Uniseed's news page announces that Exonate has named Olav Hellebø its new chief executive.
A short post on Uniseed's site reports a leadership change at Exonate, with Olav Hellebø taking the chief executive role.
Uniseed's site carries a short announcement that ENA Respiratory has added Melissa Faris to its board of directors.
Uniseed's site announces that Aravax has appointed Carsten Hellmann and Andrew Oxtoby to its board.
Uniseed announces an investment in xCystence Bio, a company developing a therapy for genetic kidney disease; no amount, stage or other investors are disclosed.
Under Breakthrough Victoria ·leads this story in the feed
Q-Sera's RAPClot blood-collection tube has debuted commercially in Japan, its first market launch, announced via a press release posted on Uniseed's news page.
Uniseed's site carries a short announcement that Ferronova has secured a further $6 million for its surgical imaging technology used in cancer operations.
Also biospectrumasia.com·Business News Australia·Biotech Dispatch·SmartCompany·Startup Daily·Startup Daily·Wholesale Investor·Wholesale Investor
Australia's Uniseed venture fund has named Dr Alastair Hick as its chief executive, with the appointment announced as the fund marks 25 years of operation.
Deals recorded from Uniseed's coverage. A round is listed once, however many of their articles mention it.
| Company | Stage | Announced | Amount | Investors |
|---|---|---|---|---|
| Kinoxis Therapeutics | Unnamed stage | 23 Sep 2026 | $6.8m | |
| Kinoxis Therapeutics | Accelerator | 23 Sep 2026 | - | |
| Kinoxis Therapeutics | Grant | 23 Sep 2026 | $2.5m | |
| ENA Respiratory | Grant | 1 Sep 2026 | $3m | |
| ENA Respiratory | Accelerator | 30 Aug 2026 | $8.3m | |
| xCystence Bio | Pre-seed | 30 Mar 2026 | - | |
| Ferronova | Series A | 17 Dec 2025 | $6m |
Companies named in Uniseed's articles, most-covered first.
| Company | What it does | Articles |
|---|---|---|
| Accellacare | 1 | |
| AND Health | 1 | |
| Aravax | Biotech company running a Phase 2 peanut allergy trial | 2 |
| Artesian VC | Alternative asset management for debt and venture capital | 1 |
| Astanor | 1 | |
| Austrade | 1 | |
| BARDA | 2 | |
| BioCurate | 1 | |
| BioScout | 1 | |
| BLUE KNIGHT | a joint initiative between Johnson & Johnson Innovation and BARDA designed to accelerate … | 1 |
| Bora Biologics | Manufacturer of Q-Sera’s recombinant ecarin | 1 |
| Brandon BioCatalyst | Investment fund and incubator for biomedical research discoveries | 1 |
| Brandon Capital | 4 | |
| Brandon Capital Partners | 1 | |
| Breakthrough Victoria | 2 | |
| Charles Consultants | 1 | |
| CSIRO | Australia's national science research agency, from which Terria spun out | 1 |
| CUREator | 1 | |
| Currus Biologics | Biotech developing the BEAT platform to unlock CAR-T cell therapy for solid tumours | 1 |
| Demea Sustainable Investment | 1 | |
| Dementia Australia | Partner in the CUREator+ Dementia and Cognitive Decline incubator program | 1 |
| Division Q | 1 | |
| ENA Respiratory | Antiviral nasal spray to prevent severe respiratory viral infections | 3 |
| Exonate | 2 | |
| Ferronova | advance image-guided cancer surgery | 1 |
| Flu Lab | 2 | |
| Gates Foundation | 1 | |
| GrainCorp Ventures | Venture capital arm investing in agtech start-ups | 1 |
| GrainInnovate | 1 | |
| Grains Research and Development Corporation | 1 | |
| Hort Innovation | 1 | |
| Johnson & Johnson Innovation | 2 | |
| Kinoxis Therapeutics | A clinical candidate that aims to provide an alternative to antipsychotics for managing a… | 1 |
| Main Sequence Ventures | 1 | |
| Medical Research Commercialisation Fund (MRCF) | 1 | |
| Medical Research Future Fund | 2 | |
| Minderoo Foundation | 2 | |
| Monash University | University partnered on Remagine Labs spin-out | 1 |
| Monash Ventures Pre-Seed Fund | 1 | |
| Naval Medical Research Command (NMRC) Clinical Trials Center | 1 | |
| Novartis Venture Fund | 1 | |
| Q-Sera | 2 | |
| Stoic Venture Capital | 2 | |
| Tenmile | 1 | |
| Terumo Corporation | Global medical innovation company providing solutions in therapeutic procedures, hospital… | 1 |
| U.S. Government | 2 | |
| UniQuest | UQ’s commercialisation company | 1 |
| UniQuest Extension Fund | 1 | |
| UniSuper | 1 | |
| University of Maryland's Center for Vaccine Development and Global Health | 1 | |
| University of Queensland | Research university where Cortisonic's underlying phononic computing research originated | 1 |
| University of Sydney | 1 | |
| US COPD Foundation | 1 | |
| US Food and Drug Administration | 1 | |
| xCystence Bio | Victorian biotechnology company developing new treatments for polycystic kidney disease | 2 |
Investors named in Uniseed's articles, most-covered first.
| Investor | What it does | Articles |
|---|---|---|
| Uniseed | Venture fund backing early-stage deep tech and life science companies | 9 |
| Biointelect Venturer | A national incubator intended to help turn early-stage infectious disease research into i… | 2 |
| Australian Government | 1 | |
| MainSequence | 1 |